Christopher Nutting

Christopher Nutting

Royal Marsden Hospital - London / United Kingdom
Others
AD Scientific Index ID: 4922986
person_outline Christopher Nutting's MOST POPULAR ARTICLES
1-) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trialCM Nutting, JP Morden, KJ Harrington, TG Urbano, SA Bhide, C Clark, ...The lancet oncology 12 (2), 127-136, 201116392011
2-) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialMS Brose, CM Nutting, B Jarzab, R Elisei, S Siena, L Bastholt, ...The Lancet 384 (9940), 319-328, 20141417*2014
3-) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trialH Mehanna, M Robinson, A Hartley, A Kong, B Foran, T Fulton-Lieuw, ...The Lancet 393 (10166), 51-60, 20197032019
4-) Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelinesV Grégoire, K Ang, W Budach, C Grau, M Hamoir, JA Langendijk, A Lee, ...Radiotherapy and Oncology 110 (1), 172-181, 20148392014
5-) Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancerU Mallick, C Harmer, B Yap, J Wadsley, S Clarke, L Moss, A Nicol, ...New England Journal of Medicine 366 (18), 1674-1685, 20127532012